Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
118
Recruiting Now
118
Top Conditions in Phase 2 / Phase 3
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT07046611 Phase 2, Phase 3
Recruiting
Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epil...
Condition
Generalized Convulsive Status Epilepticus
Enrollment
124 pts
Location
Egypt
Sponsor
Sohag University
NCT06493552 Phase 2, Phase 3
Recruiting
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Condition
Muscle-Invasive Bladder Carcinoma
Enrollment
700 pts
Location
United States
Sponsor
Vasgene Therapeutics, Inc
NCT06965998 Phase 2, Phase 3
Recruiting
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban i...
Condition
SVT
Enrollment
50 pts
Location
Canada
Sponsor
Ottawa Hospital Research Insti
NCT06478108 Phase 2, Phase 3
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
Condition
Lung Cancer
Enrollment
60 pts
Location
China
Sponsor
Second Affiliated Hospital of
NCT07655817 Phase 2, Phase 3
Recruiting
Oral Versus Intravenous Magnesium on Emergence Delirium
Condition
Magnesium
Enrollment
360 pts
Location
Egypt
Sponsor
Tanta University
NCT06956950 Phase 2, Phase 3
Recruiting
Magnesium Sulfate in Addition to Bupivacaine in Ultrasound-guided Transmuscular ...
Condition
Pain Score Reduction
Enrollment
70 pts
Location
Egypt
Sponsor
Tanta University
NCT07725523 Phase 2, Phase 3
Recruiting
Safety and Efficacy of OTL78
Condition
Prostate Cancer Surgery
Enrollment
45 pts
Location
United States
Sponsor
Clinton Bahler
NCT07264543 Phase 2, Phase 3
Recruiting
Early Methylene Blue in the Microhemodynamics of Septic Patients
Condition
Septic Shock
Enrollment
50 pts
Location
Brazil
Sponsor
Centro de Estudos e Pesquisa e
NCT05125055 Phase 2, Phase 3
Recruiting
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Condition
Oral Squamous Cell Carcinoma
Enrollment
80 pts
Location
China
Sponsor
Shanghai Jiao Tong University
NCT07542808 Phase 2, Phase 3
Recruiting
An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety ...
Condition
Knee Arthritis Osteoarthritis
Enrollment
140 pts
Location
United Arab Emirates
Sponsor
Cellcolabs Clinical SPV Limite
NCT05139017 Phase 2, Phase 3
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care i...
Condition
DLBCL
Enrollment
290 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT03660917 Phase 2, Phase 3
Recruiting
Riluzole in Patients With Spinocerebellar Ataxia Type 7
Condition
SCA7
Enrollment
34 pts
Location
Italy
Sponsor
S. Andrea Hospital
NCT03373968 Phase 2, Phase 3
Recruiting
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability St...
Condition
Duchenne Muscular Dystrophy
Enrollment
206 pts
Location
United States, Belgium, Canada
Sponsor
Italfarmaco
NCT07450443 Phase 2, Phase 3
Recruiting
Role of the Gut Vascular Barrier and Microbiota in Autism Spectrum Disorders
Condition
Autism
Enrollment
90 pts
Location
Italy
Sponsor
Fondazione I.R.C.C.S. Istituto
NCT07723963 Phase 2, Phase 3
Recruiting
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment ...
Condition
Juvenile Myoclonic Epilepsy
Enrollment
260 pts
Location
United States
Sponsor
Jazz Pharmaceuticals
NCT04893525 Phase 2, Phase 3
Recruiting
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency D...
Condition
Opioid-use Disorder
Enrollment
658 pts
Location
Canada
Sponsor
University of British Columbia
NCT06286878 Phase 2, Phase 3
Recruiting
Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes
Condition
Myocardial Infarction
Enrollment
80 pts
Location
Brazil
Sponsor
University of Sao Paulo
NCT07209878 Phase 2, Phase 3
Recruiting
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparis...
Condition
Prostate Cancer (Adenocarcinoma)
Enrollment
100 pts
Location
China
Sponsor
First Affiliated Hospital of F
NCT06820034 Phase 2, Phase 3
Recruiting
Empowering Cessation ACS South Region
Condition
Smoking Cessation
Enrollment
400 pts
Location
United States
Sponsor
University of Oklahoma
NCT07535554 Phase 2, Phase 3
Recruiting
The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 ...
Condition
Fever of Unknown Origin
Enrollment
140 pts
Location
Belgium
Sponsor
Universitaire Ziekenhuizen KU
NCT07891156 Phase 2, Phase 3
Recruiting
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight...
Condition
Type 1 Diabetes
Enrollment
40 pts
Location
Canada
Sponsor
McGill University Health Centr
NCT07606014 Phase 2, Phase 3
Recruiting
No Guts No Glory Probiotics
Condition
Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine
Enrollment
112 pts
Location
Netherlands
Sponsor
University Medical Center Gron
NCT06891833 Phase 2, Phase 3
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + ...
Condition
HER2-positive Breast Cancer
Enrollment
985 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C
NCT05664789 Phase 2, Phase 3
Recruiting
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
Condition
Autism Spectrum Disorder
Enrollment
144 pts
Location
United States
Sponsor
Stanford University
NCT06976268 Phase 2, Phase 3
Recruiting
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment...
Condition
Parkinson Disease
Enrollment
550 pts
Location
United States
Sponsor
Biohaven Therapeutics Ltd.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology